RayKnowChina Research Map
Shortlist0

Not yet recruitingNasopharyngeal carcinomaPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04890522, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 60 years; sex: all

    Registered eligibility fields

  2. Nasopharyngeal carcinoma diagnosed by pathology or cytology.

    Inclusion criterion 1

  3. Has not received prior systemic treatment for metastatic nasopharyngeal carcinoma, except for neoadjuvant chemotherapy, concurrent chemoradiotherapy, or adjuvant chemotherapy 6 months prior to the first treatment.

    Inclusion criterion 3

    Has at least one measurable target lesion based on RECIST v1.1, which is never received local treatment like radiotherapy.

    Inclusion criterion 5

    Men with reproductive capacity or women of childbearing potential must use highly effective contraceptive methods during the trial (e.g., oral contraceptives, intrauterine device, sexual abstinence or barrier method combined with spermicide), and continue contraception for 3 months after the last injection of JS001 and 6 months after the end of chemotherapy.

    Inclusion criterion 14

    Has prior therapy including anti-PD-1, anti-PD-L1, or CTLA4.

    Exclusion criterion 2

    Major surgery within 28 days prior to the randomization (not including diagnostic surgery) or plan to be conducted during the study.

    Exclusion criterion 3

  4. absolute neutrophil count ≥1.5×10\^9/ L;

    Inclusion criterion 8

    platelet count ≥ 100×10\^9/ L;

    Inclusion criterion 9

    hemoglobin ≥ 8.0 g/dL;

    Inclusion criterion 10

    aspartate transferase(AST) and alanine transferase(ALT) ≤ 1.5 ×ULN; total bilirubin ≤ 1.5×ULN (if has liver metastasis, AST and ALT ≤ 5×ULN);

    Inclusion criterion 12

    creatinine clearance >50 mL/min.

    Inclusion criterion 13

  5. Had other invasive malignant diseases, except excised basal-cell skin carcinoma, cervical carcinoma in situ, or other cancers curatively treated more than 5 years before study entry.

    Exclusion criterion 8

  6. Pregnancy or breast feeding.

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04890522, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Nasopharyngeal carcinoma diagnosed by pathology or cytology.
  • Primarily metastatic (stage IVB as defined by the International Union against Cancer and American Joint Committee on Cancer staging system for NPC, eighth edition) is not amenable for local-regional treatment or curative treatment.
  • Has not received prior systemic treatment for metastatic nasopharyngeal carcinoma, except for neoadjuvant chemotherapy, concurrent chemoradiotherapy, or adjuvant chemotherapy 6 months prior to the first treatment.
  • The Karnofsky performance status score is at least 70 points (if the decreased score is caused by the tumor, the minimum score can be 50 points after the judgment of researchers.)
  • Has at least one measurable target lesion based on RECIST v1.1, which is never received local treatment like radiotherapy.
  • Life expectancy ≥ 3 months.
  • The lab examination results of the screening must fulfill all of the following (use of any blood components, hematopoietic stimulating factors, etc. are not allowed within 14 days before screening):
  • absolute neutrophil count ≥1.5×10\^9/ L;
  • platelet count ≥ 100×10\^9/ L;
  • hemoglobin ≥ 8.0 g/dL;
  • serum albumin ≥ 2.8g/dL;
  • aspartate transferase(AST) and alanine transferase(ALT) ≤ 1.5 ×ULN; total bilirubin ≤ 1.5×ULN (if has liver metastasis, AST and ALT ≤ 5×ULN);
  • creatinine clearance >50 mL/min.
  • Men with reproductive capacity or women of childbearing potential must use highly effective contraceptive methods during the trial (e.g., oral contraceptives, intrauterine device, sexual abstinence or barrier method combined with spermicide), and continue contraception for 3 months after the last injection of JS001 and 6 months after the end of chemotherapy.
  • Has signed the Informed Consent Form.

Exclusion Criteria:

  • Allergic to monoclonal antibodies, any JS001 components, gemcitabine, cisplatin, or 5-fluorouracil.
  • Has prior therapy including anti-PD-1, anti-PD-L1, or CTLA4.
  • Major surgery within 28 days prior to the randomization (not including diagnostic surgery) or plan to be conducted during the study.
  • Active autoimmune disease requiring systemic treatment or has a history of autoimmune disease.
  • Requiring the use of cortisol (>10mg/day Prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment.
  • Allergic to macromolecular protein preparation ingredients.
  • Has central nervous system (CNS) metastasis with clinical symptoms.
  • Had other invasive malignant diseases, except excised basal-cell skin carcinoma, cervical carcinoma in situ, or other cancers curatively treated more than 5 years before study entry.
  • Has cardiac clinical symptoms or disease out of control.
  • Has an active infection or unexplained fever with more than 38.5 ℃ during screening and prior to first administration.
  • Has acquired or congenital immune-deficient disease, or active hepatitis.
  • History of drug abuse or alcohol abuse.
  • The investigator judges other factors that may lead to the forced termination of this study, including but not limited to: other serious conditions (including mental disorder) that require concomitant treatment, severe laboratory test abnormalities, family or social factors that may affect the safety of patients or the collection of trial data and samples.
  • Pregnancy or breast feeding.

Quoted from ClinicalTrials.gov, NCT04890522, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04890522, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04890522